Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.
SGLT-2 抑制劑與 pioglitazone 聯合治療對 2 型糖尿病患者心血管結果的協同改善。
Front Endocrinol (Lausanne) 2024-09-16
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
鈉葡萄糖共同轉運蛋白-2抑制劑和二肽基胺肽酶-4抑制劑聯合治療對心血管和腎臟結果的影響：隨機心血管結果試驗的荟萃分析。
Endocr Pract 2023-07-18
Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database.
Pioglitazone、SGLT2 抑制劑及其組合在第2型糖尿病患者心血管疾病和心力衰竭初級預防中的真實世界證據：來自全國性群眾資料庫的研究。
Diabetes Res Clin Pract 2023-06-06
All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
2 型糖尿病患者使用鈉葡萄糖共同運輸蛋白 2 抑製劑、葡萄糖樣胰高血糖素受體激動劑以及聯合治療的全因死亡率和心血管結果。
Diabetes Obes Metab 2023-09-05
Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
二型糖尿病患者合併使用鈉葡萄糖轉運蛋白2抑制劑和葡萄糖樣肽-1受體激動劑的效果和安全性：觀察性研究的系統性回顧和荟萃分析。
Cardiovasc Diabetol 2024-03-21
Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
鈉葡萄糖共同轉運蛋白2抑制劑與2型糖尿病患者急性冠狀動脈綜合症的主要不良心血管事件風險相關性：傾向分數匹配分析。
Cardiovasc Diabetol 2024-04-05
Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
結合 pioglitazone 與鈉葡萄糖共同運輸蛋白-2 抑制劑或葡萄糖樣肽-1 受體激動劑對第2型糖尿病結果的影響：來自國際聯合數據庫的系統性回顧、荟萃分析和實際研究。
Diabetes Obes Metab 2024-04-01
Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
第三步葡萄糖降低藥物中鈉-葡萄糖共同轉運蛋白2抑制劑和葡萄糖樣肽1受體激動劑對2型糖尿病患者心血管和死亡益處的回顧性cohort分析。
BMJ Open Diabetes Res Care 2024-05-08
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑單獨及與 SGLT2 抑制劑聯合使用在 2 型糖尿病中的心血管、腎臟及安全性結果：系統性回顧與統合分析。
Circulation 2024-08-30